Paying users zone. Data is hidden behind 
.
Get 1-month access to Gilead Sciences Inc. for $17.99, or
get full access to the entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Gilead Sciences Inc. (GILD)
Analysis of Profitability Ratios
Beginner level
Profitability ratios measure the company’s ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
Gilead Sciences Inc., profitability ratios
Based on: 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-25).
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Gilead Sciences Inc.’s gross profit margin ratio deteriorated from 2016 to 2017 and from 2017 to 2018. |
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Gilead Sciences Inc.’s operating profit margin ratio deteriorated from 2016 to 2017 and from 2017 to 2018. |
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Gilead Sciences Inc.’s net profit margin ratio deteriorated from 2016 to 2017 but then slightly improved from 2017 to 2018. |
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Gilead Sciences Inc.’s ROE deteriorated from 2016 to 2017 but then slightly improved from 2017 to 2018. |
| ROA | A profitability ratio calculated as net income divided by total assets. | Gilead Sciences Inc.’s ROA deteriorated from 2016 to 2017 but then slightly improved from 2017 to 2018. |
Gross Profit Margin
Gilead Sciences Inc., gross profit margin calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Gross profit on product sales | |
|
|
|
|
|
| Product sales | |
|
|
|
|
|
| Profitability Ratio | ||||||
| Gross profit margin1 | |
|
|
|
|
|
| Benchmarks | ||||||
| Gross Profit Margin, Competitors2 | ||||||
| Abbott Laboratories | |
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
| Biogen Inc. | |
|
|
|
|
|
| Bristol-Myers Squibb Co. | |
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
| Johnson & Johnson | |
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
| Zoetis Inc. | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-25).
1 2018 Calculation
Gross profit margin = 100 × Gross profit on product sales ÷ Product sales
= 100 × ÷ =
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Gilead Sciences Inc.’s gross profit margin ratio deteriorated from 2016 to 2017 and from 2017 to 2018. |
Operating Profit Margin
Gilead Sciences Inc., operating profit margin calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Income from operations | |
|
|
|
|
|
| Product sales | |
|
|
|
|
|
| Profitability Ratio | ||||||
| Operating profit margin1 | |
|
|
|
|
|
| Benchmarks | ||||||
| Operating Profit Margin, Competitors2 | ||||||
| Abbott Laboratories | |
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
| Biogen Inc. | |
|
|
|
|
|
| Bristol-Myers Squibb Co. | |
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
| Johnson & Johnson | |
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
| Zoetis Inc. | |
|
|
|
|
|
| Operating Profit Margin, Sector | ||||||
| Pharmaceuticals & Biotechnology | |
|
|
|
|
|
| Operating Profit Margin, Industry | ||||||
| Health Care | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-25).
1 2018 Calculation
Operating profit margin = 100 × Income from operations ÷ Product sales
= 100 × ÷ =
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Gilead Sciences Inc.’s operating profit margin ratio deteriorated from 2016 to 2017 and from 2017 to 2018. |
Net Profit Margin
Gilead Sciences Inc., net profit margin calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income attributable to Gilead | |
|
|
|
|
|
| Product sales | |
|
|
|
|
|
| Profitability Ratio | ||||||
| Net profit margin1 | |
|
|
|
|
|
| Benchmarks | ||||||
| Net Profit Margin, Competitors2 | ||||||
| Abbott Laboratories | |
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
| Biogen Inc. | |
|
|
|
|
|
| Bristol-Myers Squibb Co. | |
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
| Johnson & Johnson | |
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
| Zoetis Inc. | |
|
|
|
|
|
| Net Profit Margin, Sector | ||||||
| Pharmaceuticals & Biotechnology | |
|
|
|
|
|
| Net Profit Margin, Industry | ||||||
| Health Care | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-25).
1 2018 Calculation
Net profit margin = 100 × Net income attributable to Gilead ÷ Product sales
= 100 × ÷ =
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Gilead Sciences Inc.’s net profit margin ratio deteriorated from 2016 to 2017 but then slightly improved from 2017 to 2018. |
Return on Equity (ROE)
Gilead Sciences Inc., ROE calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income attributable to Gilead | |
|
|
|
|
|
| Total Gilead stockholders’ equity | |
|
|
|
|
|
| Profitability Ratio | ||||||
| ROE1 | |
|
|
|
|
|
| Benchmarks | ||||||
| ROE, Competitors2 | ||||||
| Abbott Laboratories | |
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
| Biogen Inc. | |
|
|
|
|
|
| Bristol-Myers Squibb Co. | |
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
| Johnson & Johnson | |
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
| Zoetis Inc. | |
|
|
|
|
|
| ROE, Sector | ||||||
| Pharmaceuticals & Biotechnology | |
|
|
|
|
|
| ROE, Industry | ||||||
| Health Care | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-25).
1 2018 Calculation
ROE = 100 × Net income attributable to Gilead ÷ Total Gilead stockholders’ equity
= 100 × ÷ =
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Gilead Sciences Inc.’s ROE deteriorated from 2016 to 2017 but then slightly improved from 2017 to 2018. |
Return on Assets (ROA)
Gilead Sciences Inc., ROA calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income attributable to Gilead | |
|
|
|
|
|
| Total assets | |
|
|
|
|
|
| Profitability Ratio | ||||||
| ROA1 | |
|
|
|
|
|
| Benchmarks | ||||||
| ROA, Competitors2 | ||||||
| Abbott Laboratories | |
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
| Biogen Inc. | |
|
|
|
|
|
| Bristol-Myers Squibb Co. | |
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
| Johnson & Johnson | |
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
| Zoetis Inc. | |
|
|
|
|
|
| ROA, Sector | ||||||
| Pharmaceuticals & Biotechnology | |
|
|
|
|
|
| ROA, Industry | ||||||
| Health Care | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-25).
1 2018 Calculation
ROA = 100 × Net income attributable to Gilead ÷ Total assets
= 100 × ÷ =
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROA | A profitability ratio calculated as net income divided by total assets. | Gilead Sciences Inc.’s ROA deteriorated from 2016 to 2017 but then slightly improved from 2017 to 2018. |